HYPAQUE-M,75% Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Hypaque-m,75%, and when can generic versions of Hypaque-m,75% launch?
Hypaque-m,75% is a drug marketed by Ge Healthcare and is included in one NDA.
The generic ingredient in HYPAQUE-M,75% is diatrizoate meglumine; diatrizoate sodium. There is one drug master file entry for this compound. Four suppliers are listed for this compound. Additional details are available on the diatrizoate meglumine; diatrizoate sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Hypaque-m,75%
A generic version of HYPAQUE-M,75% was approved as diatrizoate meglumine; diatrizoate sodium by ADAPTIS on June 27th, 2022.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for HYPAQUE-M,75%?
- What are the global sales for HYPAQUE-M,75%?
- What is Average Wholesale Price for HYPAQUE-M,75%?
Summary for HYPAQUE-M,75%
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 4 |
| DailyMed Link: | HYPAQUE-M,75% at DailyMed |
Recent Clinical Trials for HYPAQUE-M,75%
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Institute of Liver and Biliary Sciences, India | N/A |
| Cephalon | Phase 2 |
| Dartmouth-Hitchcock Medical Center | Phase 2 |
US Patents and Regulatory Information for HYPAQUE-M,75%
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ge Healthcare | HYPAQUE-M,75% | diatrizoate meglumine; diatrizoate sodium | INJECTABLE;INJECTION | 010220-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
